Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Report Date: March 9, 2023
Reporting Period: Three months ended December 31, 2022 (Q4 2022)
This filing serves as a notification that the Company issued a press release on March 9, 2023, announcing financial results for the quarter ended December 31, 2022. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Revenue, profit, cash flow, margins, debt, and liquidity values are not present in the source text.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance compared to the prior comparable period. It only confirms the announcement of results for the three months ended December 31, 2022.
Guidance, Outlook, and Risks
Management Commentary: The Company scheduled a conference call for 8:00 AM ET on March 9, 2023, to discuss the results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover sheet.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 2022 revenue, net income, and cash flow figures.
- Verify the details of the conference call held on March 9, 2023, for management's outlook and guidance.
- Confirm the status of the Interim Chief Financial Officer, Jennifer Cote, as the signing authority.
- Check subsequent filings for the full audited financial statements if this 8-K only references unaudited results.